Perrigo launches generic BenzaClin Pump

DUBLIN — Perrigo on Monday announced the FDA approval and launch of its generic BenzaClin (clindamycin phosphate 1% and benzoyl peroxide 5%) Pump topical gel. 

 

The drug is indicated to treat acne vulgaris, and the company has already begun shipping to customers. 

 

“This Rx product approval and launch demonstrate the team's ability to leverage Perrigo's manufacturing expertise in order to provide our customers with the latest technologies,” Perrigo CEO John Hendrickson said. “Providing our customers with convenient, cost effective technologies like the BenzaClin Pump furthers Perrigo's commitment of delivering quality affordable healthcare products around the world.